These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10885433)

  • 41. Changes in sputum composition during 15 min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease.
    Toungoussova O; Migliori GB; Foschino Barbaro MP; Esposito LM; Dragonieri S; Carpagnano GE; Salerno FG; Neri M; Spanevello A
    Respir Med; 2007 Jul; 101(7):1543-8. PubMed ID: 17258444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma.
    Shaw DE; Berry MA; Hargadon B; McKenna S; Shelley MJ; Green RH; Brightling CE; Wardlaw AJ; Pavord ID
    Chest; 2007 Dec; 132(6):1871-5. PubMed ID: 17925424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease.
    Bel EH; Zwinderman AH; Timmers MC; Dijkman JH; Sterk PJ
    Thorax; 1991 Jan; 46(1):9-14. PubMed ID: 1871705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease.
    Ikeda A; Nishimura K; Koyama H; Tsukino M; Hajiro T; Mishima M; Izumi T
    Respiration; 1999; 66(2):119-23. PubMed ID: 10202314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease.
    Pisi R; Aiello M; Zanini A; Tzani P; Paleari D; Marangio E; Spanevello A; Nicolini G; Chetta A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1191-7. PubMed ID: 26150710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease.
    Zanini A; Cherubino F; Zampogna E; Croce S; Pignatti P; Spanevello A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1155-61. PubMed ID: 26124655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease.
    Nisar M; Walshaw M; Earis JE; Pearson MG; Calverley PM
    Thorax; 1990 Mar; 45(3):190-4. PubMed ID: 2330551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of sputum induction methods: ultrasonic vs compressed-air nebulizer and hypertonic vs isotonic saline inhalation.
    Loh LC; Eg KP; Puspanathan P; Tang SP; Yip KS; Vijayasingham P; Thayaparan T; Kumar S
    Asian Pac J Allergy Immunol; 2004 Mar; 22(1):11-7. PubMed ID: 15366653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aerosol pentamidine-induced bronchoconstriction. Predictive factors and preventive therapy.
    Quieffin J; Hunter J; Schechter MT; Lawson L; Ruedy J; Paré P; Montaner JS
    Chest; 1991 Sep; 100(3):624-7. PubMed ID: 1832372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of sputum induction in lung transplant recipients.
    van den Berg JW; Slebos DJ; Postma DS; Dijkhuizen B; Koëter GH; Timens W; der van Bij W; Kauffman HF
    Clin Transplant; 2004 Oct; 18(5):605-12. PubMed ID: 15344968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of sputum induction using high-output and low-output ultrasonic nebulizers in normal subjects and patients with COPD.
    Kelly MG; Brown V; Martin SL; Ennis M; Elborn JS
    Chest; 2002 Sep; 122(3):955-9. PubMed ID: 12226038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Salbutamol in Mixed Obstructive and Restrictive Pattern Spirometry.
    Tuladhar LR; Tamrakar Tuladhar ET
    Kathmandu Univ Med J (KUMJ); 2017 Oct.-Dec.; 15(60):279-283. PubMed ID: 30580341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Measures of bronchodilator response of FEV
    Torén K; Bake B; Olin AC; Engström G; Blomberg A; Vikgren J; Hedner J; Brandberg J; Persson HL; Sköld CM; Rosengren A; Bergström G; Janson C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():973-980. PubMed ID: 28356729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two puffs of 90 microg albuterol prior to 3% saline sputum induction results in less FEV-1 decline than single concentration 25 mg/ml methacholine challenge.
    Hagan JB; Madaan A; Kim CK
    Allergy Asthma Proc; 2006; 27(5):397-401. PubMed ID: 17063670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response to oral corticosteroid in patients with chronic obstructive pulmonary disease.
    Koyama H; Nishimura K; Mio T; Izumi T
    Intern Med; 1992 Oct; 31(10):1179-84. PubMed ID: 1286223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment.
    Perng DW; Huang HY; Chen HM; Lee YC; Perng RP
    Chest; 2004 Aug; 126(2):375-81. PubMed ID: 15302720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of sputum induction during exacerbations of COPD.
    Bathoorn E; Liesker J; Postma D; Koëter G; van Oosterhout AJ; Kerstjens HA
    Chest; 2007 Feb; 131(2):432-8. PubMed ID: 17296644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.
    Molimard M; Bourcereau J; Le Gros V; Bourdeix I
    Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.